TKIs vs. Pertuzumab in HER2+ Breast Cancer Patients With Active Brain Metastases (HER2BRAIN)
Status:
Not yet recruiting
Trial end date:
2025-09-30
Target enrollment:
Participant gender:
Summary
This is a prospective, randomized, 2-arm, Phrase 2, superiority and multicenter study to
compare the efficiency of Anti-HER2 TKI versus Pertuzumab in Combination With Dose-dense
Trastuzumab and Taxane in HER2-positive breast cancer patients with active refractory brain
metastases.
Phase:
Phase 2
Details
Lead Sponsor:
Second Affiliated Hospital, School of Medicine, Zhejiang University
Collaborators:
Peking University International Hospital Sun Yat-sen University Zhejiang University